Clinical Trials Browser

Phase 3 × osimertinib × 90 days × Clear all

NCT06417814 2026-03-02

TROPION-Lung15

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-02-27

LAURA

Phase 3 Active not recruiting

216 enrolled 25 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06970639 2026-02-12

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Phase 3 Recruiting

NSCLC Patients With Brain Metastasis

NCT04487080 2026-02-04

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT07376382 2026-02-02

SYNSTAR-02

Phase 3 Not yet recruiting

NSCLC

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05624996 2026-01-14

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT04765059 2026-01-13

COMPEL

Phase 3 Active not recruiting

98 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT05120349 2026-01-12

ADAURA2

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT02511106 2026-01-05

ADAURA

Phase 3 Active not recruiting

682 enrolled 20 charts 2 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT05629234 2025-12-24

ROSY-T

Phase 3 Active not recruiting

Neoplasms